GlassScriptPhysician profile
Richard J Egan
NPI 1972579126
$21,386.03
in general payments reported to CMS, 2019-2025
53 companies · $3,833 in 2025
The $3,833 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,374 · 2020: $2,195 · 2021: $3,288 · 2022: $3,000 · 2023: $3,270 · 2024: $3,427 · 2025: $3,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,529.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,758.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $2,109.99 | 2019-2025 | |
| Abbvie INC. | $2,096.26 | 2019-2025 | Ubrelvy, Linzess, Qulipta |
| Glaxosmithkline, LLC. | $1,938.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,390.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $945.06 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $903.44 | 2019-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $831.58 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $662.23 | 2019-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $657.62 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $567.74 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $565.81 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $533.81 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $467.88 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Amarin Pharma, INC. | $418.14 | 2019-2022 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $358.73 | 2019-2025 | Eliquis, Camzyos |
| Lundbeck LLC | $347.02 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $340.99 | 2019-2025 | |
| Dexcom, INC. | $319.96 | 2021-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $282.25 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $274.27 | 2024-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $269.53 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $256.65 | 2019-2023 | |
| Esperion Therapeutics, INC. | $239.40 | 2020-2025 | Nexletol |
| Abiomed | $201.36 | 2024-2025 | Impella |
| Biohaven Pharmaceutical Holding Company LTD. | $160.69 | 2022 | |
| Phathom Pharmaceuticals, INC. | $157.82 | 2023-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $145.00 | 2020-2025 | Seglentis, Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.61 | 2019-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $125.76 | 2025 | Zenpep |
| Teva Pharmaceuticals USA, INC. | $111.47 | 2020-2023 | Airduo Digihaler |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.29 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $81.36 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.50 | 2019-2025 | Eohilia |
| Azurity Pharmaceuticals, INC. | $53.13 | 2024 | Edarbi |
| Pulmonx Corporation | $53.06 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Dynavax Technologies Corporation | $52.03 | 2024 | Heplisav-B |
| Ultragenyx Pharmaceutical INC. | $44.80 | 2021 | |
| Horizon Therapeutics Plc | $41.36 | 2022-2023 | Krystexxa |
| Dermira, INC. | $38.65 | 2020 | |
| Amneal Pharmaceuticals LLC | $36.70 | 2022-2024 | Unithroid |
| Inspire Medical Systems, INC. | $33.88 | 2024 | Inspire |
| Almatica Pharma LLC | $29.77 | 2022-2025 | Loreev Xr |
| Arbor Pharmaceuticals, INC. | $27.76 | 2019-2020 | |
| Lifescan, INC. | $24.64 | 2023 | |
| Si-Bone, INC. | $19.70 | 2024 | |
| Collegium Pharmaceutical, INC. | $19.66 | 2024 | Xtampza |
| Xeris Pharmaceuticals, INC. | $19.28 | 2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $17.65 | 2019 | |
| Protega Pharmaceutials INC | $16.71 | 2022 | |
| Phadia US INC. | $14.70 | 2023 | Immunocap |
| Eisai INC. | $12.78 | 2021 | |
| Genentech USA, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.